2023 World Conference on Lung Cancer (Posters)-EP07.01. Ablation of Early-Stage Non-Small Cell Lung Cancer in Patients With Interstitial Lung Disease: A Multicenter Retrospective Cohort Study

EP07.01. Ablation of Early-Stage Non-Small Cell Lung Cancer in Patients With Interstitial Lung Disease: A Multicenter Retrospective Cohort Study - PDF(Slides)

Back to course

Pdf Summary

A recent multicenter cohort study examined the safety and efficacy of percutaneous ablation as a treatment option for early-stage non-small cell lung cancer (NSCLC) in patients with interstitial lung disease (ILD). ILD patients are at an increased risk of developing NSCLC, but traditional treatments such as surgery, radiation therapy, and chemotherapy can lead to exacerbations of ILD and even death. The study included 33 ILD patients who underwent ablation of stage I-II NSCLC at three health systems. The primary outcome measured was major adverse events within 90 days of the procedure.<br /><br />The results showed that out of the 42 ablation sessions performed, 14.3% resulted in major adverse events. These events included bronchopleural fistula, hemothorax, temporary hypoxia, and bronchopulmonary hemorrhage. The length of hospital stay was relatively short, with a median of 1.0-2.0 days. The study also found that the local tumor control rate was 73% for stage I NSCLC and 75% for stage II NSCLC, which is comparable to rates seen in patients without ILD.<br /><br />Based on these findings, the authors concluded that percutaneous ablation appears to be a reasonable and safe treatment option for early-stage NSCLC in patients with ILD. It is important to note that the risk of acute exacerbation of ILD following ablation is still unclear due to limited data. Nonetheless, this study suggests that the benefits of ablation in terms of tumor control outweigh the risks of worsening ILD in carefully selected patients.<br /><br />Further research is needed to better understand the long-term outcomes and potential risks associated with ablation in ILD patients. However, these findings provide valuable insights into a potential treatment option for ILD patients with early-stage NSCLC who may not be eligible for traditional therapies.

Asset Subtitle

Florian Fintelmann

Meta Tag

Speaker Florian Fintelmann

Topic Early-Stage NSCLC: Best Practice

Keywords

percutaneous ablation

non-small cell lung cancer

interstitial lung disease

safety

efficacy

early-stage NSCLC

major adverse events

hospital stay

tumor control

potential risks